Effect of methylene blue on treatment of COVID-19 patients
Phase 3
- Conditions
- Covid-19.COVID-19, TreatmentU07.1
- Registration Number
- IRCT20191228045924N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Confirmed case of Covid-19 (by RT-PCR, HRCT)
Admission to intensive care unit
Need for intubation and mechanical ventilation (PaO2/FiO2 < 100-200)
Written informed consent
Exclusion Criteria
Pregnancy and breastfeeding
G6PDH deficiency
Severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
Active chronic hepatitis
Severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit
Patients with history of allergic reaction or significant sensitivity to methylene blue
Treatment with immunosuppressive agents
Use of other investigational drugs in the moment of inclusion
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Saturated pressure oxygen (SPO2). Timepoint: Third day, fifth day, tenth day. Method of measurement: Pulse micrometre.;Respiratory rate in one minute. Timepoint: Third day, fifth day, tenth day. Method of measurement: Physical exam.
- Secondary Outcome Measures
Name Time Method Mortality rate in both groups. Timepoint: Day 28. Method of measurement: Review of medical records.;Hospital stay. Timepoint: At the beginning of the study and the end of the trial. Method of measurement: Number of days.